Details of the Drug

General Information of Drug (ID: DMYGJQO)

Drug Name
Ponatinib
Synonyms Iclusig (TN)
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 532.6
Topological Polar Surface Area (xlogp) 4.1
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 24 hours (in cancer patients with 45 mg ponatinib once daily) [3]
Metabolism
The drug is metabolized via the esterases and/or amidases [4]
Vd
The volume of distribution (Vd) of drug is 1223 L [5]
Chemical Identifiers
Formula
C29H27F3N6O
IUPAC Name
3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
Canonical SMILES
CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
InChI
InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
InChIKey
PHXJVRSECIGDHY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
24826799
ChEBI ID
CHEBI:78543
CAS Number
943319-70-8
DrugBank ID
DB08901
TTD ID
D0H0EQ
VARIDT ID
DR00204
INTEDE ID
DR1315
ACDINA ID
D00541

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Modulator [6]
Proto-oncogene c-Ret (RET) TT4DXQT RET_HUMAN Modulator [6]
Tyrosine-protein kinase ABL1 (ABL) TT3PJMV ABL1_HUMAN Modulator [6]
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Modulator [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [7]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute lymphoblastic leukaemia
ICD Disease Classification 2A85
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosine-protein kinase Kit (KIT) DTT KIT 2.06E-01 -0.1 -0.14
Fms-like tyrosine kinase 3 (FLT-3) DTT FLT3 2.11E-01 -0.05 -0.16
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 9.45E-01 -5.34E-02 -9.01E-02
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 9.96E-01 -3.17E-03 -1.84E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ponatinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Ponatinib and Acalabrutinib. Mature B-cell lymphoma [2A85] [83]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Ponatinib and Ibrutinib. Mature B-cell lymphoma [2A85] [83]
Coadministration of a Drug Treating the Disease Different from Ponatinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Ponatinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [84]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Ponatinib caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [84]
Arn-509 DMT81LZ Moderate Increased metabolism of Ponatinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [84]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Ponatinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [85]
Troleandomycin DMUZNIG Major Decreased metabolism of Ponatinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [84]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Ponatinib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [86]
Talazoparib DM1KS78 Moderate Decreased clearance of Ponatinib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [87]
Tucatinib DMBESUA Major Decreased metabolism of Ponatinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Ponatinib and Levomilnacipran. Chronic pain [MG30] [88]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Ponatinib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [84]
MK-8228 DMOB58Q Moderate Decreased metabolism of Ponatinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [83]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Ponatinib and Vortioxetine. Depression [6A70-6A7Z] [88]
SODIUM CITRATE DMHPD2Y Minor Decreased absorption of Ponatinib due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [84]
Stiripentol DMMSDOY Moderate Decreased metabolism of Ponatinib caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Tazemetostat DMWP1BH Moderate Increased metabolism of Ponatinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [84]
Ripretinib DM958QB Moderate Decreased clearance of Ponatinib due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [84]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Ponatinib and Avapritinib. Gastrointestinal stromal tumour [2B5B] [83]
Cobicistat DM6L4H2 Major Decreased metabolism of Ponatinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Aliskiren DM1BV7W Moderate Decreased clearance of Ponatinib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [89]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Ponatinib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [83]
Naloxegol DML0B41 Minor Decreased clearance of Ponatinib due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [90]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Ponatinib caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [91]
Ceritinib DMB920Z Major Decreased metabolism of Ponatinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [84]
PF-06463922 DMKM7EW Moderate Increased metabolism of Ponatinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [84]
Selpercatinib DMZR15V Moderate Decreased metabolism of Ponatinib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [92]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Ponatinib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [93]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Ponatinib and Idelalisib. Mature B-cell leukaemia [2A82] [94]
GDC-0199 DMH0QKA Major Decreased clearance of Ponatinib due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [84]
IPI-145 DMWA24P Moderate Decreased metabolism of Ponatinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [95]
Arry-162 DM1P6FR Major Increased risk of bleeding by the combination of Ponatinib and Arry-162. Melanoma [2C30] [83]
LGX818 DMNQXV8 Major Increased risk of bleeding by the combination of Ponatinib and LGX818. Melanoma [2C30] [83]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Ponatinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [84]
Ubrogepant DM749I3 Moderate Decreased clearance of Ponatinib due to the transporter inhibition by Ubrogepant. Migraine [8A80] [96]
Rimegepant DMHOAUG Moderate Decreased clearance of Ponatinib due to the transporter inhibition by Rimegepant. Migraine [8A80] [97]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Ponatinib and Tecfidera. Multiple sclerosis [8A40] [98]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Ponatinib and Siponimod. Multiple sclerosis [8A40] [84]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Ponatinib and Ocrelizumab. Multiple sclerosis [8A40] [99]
Fedratinib DM4ZBK6 Major Increased risk of bleeding by the combination of Ponatinib and Fedratinib. Myeloproliferative neoplasm [2A20] [83]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Ponatinib and Vorapaxar. Myocardial infarction [BA41-BA43] [83]
Netupitant DMEKAYI Moderate Decreased metabolism of Ponatinib caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [83]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Ponatinib caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [100]
Abametapir DM2RX0I Moderate Decreased metabolism of Ponatinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [101]
Lefamulin DME6G97 Moderate Decreased metabolism of Ponatinib caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [102]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Ponatinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [83]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Ponatinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [91]
LEE011 DMMX75K Moderate Decreased metabolism of Ponatinib caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [83]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Ponatinib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [100]
Elagolix DMB2C0E Moderate Increased metabolism of Ponatinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [84]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Ponatinib and Betrixaban. Venous thromboembolism [BD72] [83]
⏷ Show the Full List of 49 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ponatinib Hydrochloride eq 10mg base tablet eq 10mg base Tablet Oral
Ponatinib Hydrochloride eq 15mg base tablet eq 15mg base Tablet Oral
Ponatinib Hydrochloride eq 30mg base tablet eq 30mg base Tablet Oral
Ponatinib Hydrochloride eq 45mg base tablet eq 45mg base Tablet Oral
Ponatinib 15 mg tablet 15 mg Oral Tablet Oral
Ponatinib 30 mg tablet 30 mg Oral Tablet Oral
Ponatinib 45 mg tablet 45 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5890).
2 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08901)
8 Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Pharmacol Drug Dev. 2015 Sep;4(5):354-60.
9 Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites. J Pharmacol Exp Ther. 2017 Oct;363(1):12-19.
10 Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Onco Targets Ther. 2013 Aug 20;6:1111-8.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
21 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
22 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
23 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
24 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
25 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
26 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
27 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
28 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
29 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
30 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
31 Drug Interactions Flockhart Table
32 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
33 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
34 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
35 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
36 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
37 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
38 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
39 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
40 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
41 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
42 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
43 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
44 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
45 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
46 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
47 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
48 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
49 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
50 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
51 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
52 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
53 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
54 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
55 New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
56 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
57 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
58 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
59 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
60 National Cancer Institute Drug Dictionary (drug id 452042).
61 Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
62 Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
63 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
64 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
65 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
66 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
67 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
68 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
69 National Cancer Institute Drug Dictionary (drug name Zeteletinib).
70 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
71 Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15.
72 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
73 Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25.
74 Company report (Deciphera Pharmaceuticals: Tumor-Targeted Programs and Indications)
75 Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008 Mar 13;51(5):1252-9.
76 KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
77 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
78 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
79 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
80 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
81 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
82 Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
83 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
84 Cerner Multum, Inc. "Australian Product Information.".
85 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
86 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
87 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
88 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
89 Canadian Pharmacists Association.
90 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
91 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
92 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
93 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
94 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
95 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
96 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
97 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
98 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
99 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
100 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
101 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
102 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.